Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...

The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

The pharmaceutical company AstraZeneca has completed the transition to a fully electric vehicle fleet in Switzerland. All of ...

AstraZeneca's new therapy, camizestrant, shows promising results in improving survival rates for patients with advanced ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

Kiniksa will now focus its development efforts on the IL-1 blocker KPL-387, which it is testing for recurrent pericarditis ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Find insight on AstraZeneca, Celltrion and more in the latest Market Talks covering the Health Care sector.

New York State Common Retirement Fund grew its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% during the 4th ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...